Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy.

about

Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy.

Item

http://www.wikidata.org/entity/Q38711101

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Neuroendocrine tumors of the g ...... ole of cytotoxic chemotherapy.

@en

type

Item

label

Neuroendocrine tumors of the g ...... ole of cytotoxic chemotherapy.

@en

prefLabel

Neuroendocrine tumors of the g ...... ole of cytotoxic chemotherapy.

@en

P1476

Neuroendocrine tumors of the g ...... ole of cytotoxic chemotherapy.

@en

P2093

Michael Michael

http://www.w3.org/2001/XMLSchema#string

Sumitra Ananda

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin

Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours

Gastroenteropancreatic neuroendocrine tumours

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

Radionuclide therapy in neuroendocrine tumours: a systematic review.

Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).

P304

391-401

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2016.1146135

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mustafa Khasraw

P577

2016-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26808925

http://www.w3.org/2001/XMLSchema#string